HCV supplemental testing
This article was originally published in The Gray Sheet
Chiron Corp. asks FDA to amend its guidelines for blood donor screening for the hepatitis C virus to state that only licensed supplemental tests should be used. The April 23 guidelines state that donors should be tested with supplemental assays, and specifically cite Chiron's RIBA HCV 2.0 and Abbott's Matrix HCV tests. FDA currently has licensed only the Chiron test, the company says.
You may also be interested in...
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.